do-me/EUR-LEX huggingface dataset:
State aid – Decision to raise no objections 2021/C 324/06
Date: 2021-08-12
Institutions: EFTA Surveillance Authority
Subjects: European Economic Area, Norway, State aid, control of State aid, energy industry, energy resources, reduction of gas emissions








C_2021324EN.01001001.xml










12.8.2021   


EN


Official Journal of the European Union


C 324/10






State aid – Decision to raise no objections
(2021/C 324/06)
The EFTA Surveillance Authority raises no objections to the following state aid measure:






Date of adoption of the decision


29 April 2021




Case No


86666




Decision No


034/21/COL




EFTA State


Norway




Title (and/or name of the beneficiary)


State aid to support dedicated alternative fuels infrastructure 2021-2025




Legal basis


Enova Programmes




Type of measure


Scheme




Objective


Environmental




Form of aid


Grants




Budget


NOK 200 million




Intensity


40 % for large enterprises, 50 % for medium-sized enterprises and 60 % for small enterprises




Duration


Until 31 December 2025




Economic sectors


Open to all sectors




Name and address of the granting authority







Enova SF




Brattørkaia 17A




N-7010 Trondheim




NORWAY








The authentic text of the decision, from which all confidential information has been removed, can be found on the EFTA Surveillance Authority’s website: http://www.eftasurv.int/state-aid/state-aid-register/decisions/
Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 44(5) of Regulation (EU) 528/2012 in the second half of 2020 2021/C 324/08 Subcommittee I on the free movement of goods To be noted by the EEA Joint Committee
Date: 2021-08-12
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, biocide, chemical product, dangerous substance, free movement of goods, market approval, marketing standard








C_2021324EN.01001201.xml










12.8.2021   


EN


Official Journal of the European Union


C 324/12






Dangerous substances – List of authorisation decisions taken by the EEA EFTA States in accordance with Article 44(5) of Regulation (EU) 528/2012 in the second half of 2020
(2021/C 324/08)
Subcommittee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 225/2013 of 13 December 2013, the EEA Joint Committee is invited to note the following lists concerning authorisation decisions adopted on the basis of Article 44(5) of Regulation (EU) No 528/2012 for the period 1 July – 31 December 2020, at their meeting on 19 March 2021.




ANNEX
List of authorisation decisions
The following authorisation decisions in accordance with Article 44(5) of Regulation (EU) No 528/2012 have been taken in the EEA EFTA States during the period 1 July – 31 December 2020:








Biocidal Product Name


Union authorisation decisions under Article 44(5) of Regulation (EU) No 528/2012


Country


Date of decision




ClearKlens product based on IPA


32020R1147


Iceland


20.11.2020




ClearKlens product based on IPA


32020R1147


Liechtenstein


16.11.2020




ClearKlens product based on IPA


32020R1147


Norway


16.11.2020




HYPRED’s octanoic acid based products


32020R0579


Iceland


13.8.2020




HYPRED’s octanoic acid based products


32020R0579


Liechtenstein


20.7.2020




HYPRED’s octanoic acid based products


32020R0579


Norway


19.8.2020




INSECTICIDES FOR HOME USE’


32020R0704


Iceland


20.11.2020




INSECTICIDES FOR HOME USE’


32020R0704


Liechtenstein


22.9.2020




INSECTICIDES FOR HOME USE’


32020R0704


Norway


12.10.2020




Iodine based products – CID LINES NV


32020R1187


Iceland


17.12.2020




Iodine based products – CID LINES NV


32020R1187


Liechtenstein


30.11.2020




Iodine based products – CID LINES NV


32020R1187


Norway


8.12.2020




SOPURCLEAN


32020R0580


Iceland


13.8.2020




SOPURCLEAN


32020R0580


Liechtenstein


21.7.2020




SOPURCLEAN


32020R0580


Norway


18.8.2020
Non-opposition to a notified concentration (Case M.10277 — Geely/Futaihua/JV) (Text with EEA relevance) 2021/C 332/01
Date: 2021-08-12
Institutions: Directorate-General for Competition, European Commission
Subjects: China, consultancy, economic concentration, electronics industry, merger control, motor car, motor vehicle industry, provision of services, vehicle parts








C_2021332EN.01000101.xml










18.8.2021   


EN


Official Journal of the European Union


C 332/1






Non-opposition to a notified concentration
(Case M.10277 — Geely/Futaihua/JV)
(Text with EEA relevance)
(2021/C 332/01)
On 12 August 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10277. EUR-Lex is the online access to European law.






(1)  OJ L 24, 29.1.2004, p. 1.
Non-opposition to a notified concentration (Case M.10102 – VIG / AEGON CEE) (Text with EEA relevance) 2022/C 93/04
Date: 2021-08-12
Institutions: Directorate-General for Competition, European Commission
Subjects: economic concentration, holding company, insurance company, merger control, pension fund








C_2022093EN.01000401.xml










28.2.2022   


EN


Official Journal of the European Union


C 93/4






Non-opposition to a notified concentration
(Case M.10102 – VIG / AEGON CEE)
(Text with EEA relevance)
(2022/C 93/04)
On 12 August 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the ‘Competition policy’ website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10102. EUR-Lex is the online point of access to European Union law.






(1)  OJ L 24, 29.1.2004, p. 1.
State aid – Decision to raise no objections 2021/C 324/07
Date: 2021-08-12
Institutions: EFTA Surveillance Authority
Subjects: European Economic Area, Norway, State aid, aid to undertakings, audiovisual production, control of State aid, coronavirus disease, culture industry, epidemic








C_2021324EN.01001101.xml










12.8.2021   


EN


Official Journal of the European Union


C 324/11






State aid – Decision to raise no objections
(2021/C 324/07)
The EFTA Surveillance Authority raises no objections to the following state aid measure:






Date of adoption of the decision


6 May 2021




Case No


86794




Decision No


036/21/COL




EFTA State


Norway




Title (and/or name of the beneficiary)


COVID-19 scheme for producers of cultural films




Legal basis


Regulation on aid to audio-visual production




Type of measure


Scheme




Objective


To ensure that the disruptions caused by the COVID-19 outbreak do not undermine the viability of producers of cultural films and the future production of cultural film.




Form of aid


Direct grant




Budget


NOK 10 million




Intensity


A grant of up to 100% of the estimated loss of income from box-office revenue from 13 March to 30 September 2020.




Duration


6 May – 31 December 2021




Economic sectors


Audiovisual production




Name and address of the granting authority







Norwegian Film Institute




P.O. Box 482




N-0105 Oslo




NORWAY








The authentic text of the decision, from which all confidential information has been removed, can be found on the EFTA Surveillance Authority’s website: http://www.eftasurv.int/state-aid/state-aid-register/decisions/
Case C-496/21: Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12 August 2021 — H. Ltd. v Federal Republic of Germany
Date: 2021-08-12
Institutions: Court of Justice
Subjects: health legislation, medical device, pharmaceutical legislation, pharmaceutical product








C_2021471EN.01002502.xml










22.11.2021   


EN


Official Journal of the European Union


C 471/25






Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12 August 2021 — H. Ltd. v Federal Republic of Germany
(Case C-496/21)
(2021/C 471/32)
Language of the case: German

Referring court

Bundesverwaltungsgericht

Parties to the main proceedings


Appellant on a point of law: H. Ltd.

Respondent in the appeal on a point of law: Federal Republic of Germany

Questions referred







1.


Can the principal intended action of a substance be pharmacological within the meaning of Article 1(2)(a) of Directive 93/42/EEC (1) even if it is not based on a receptor-mediated mode of action and the substance is not absorbed by the human body but remains on and reacts with the surface of, for example, the mucosa? On what criteria should a distinction be drawn between pharmacological and non-pharmacological means, in particular physico-chemical means, in such a case?










2.


Can a product be regarded as a substance-based medical device within the meaning of Article 1(2)(a) of Directive 93/42/EEC if, according to current scientific knowledge, the mode of action of the product is open to debate and it is thus not possible to definitively determine whether the principal intended action is achieved by pharmacological or physico-chemical means?










3.


In such a case, is the classification of the product as a medicinal product or as a medical device to be carried out on the basis of an overall assessment of its other properties and all other circumstances, or, in so far as it is intended to prevent, treat or alleviate diseases, is the product to be regarded as a medicinal product by presentation within the meaning of Article 1(2)(a) of Directive 2001/83/EC, (2) irrespective of whether or not a specific medicinal effect is being claimed?










4.


Does the primacy of the regime governing medicinal products also apply in such a case in accordance with Article 2(2) of Directive 2001/83/EC?






(1)  Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ 1993 L 169, p. 1), as last amended by Directive 2007/45/EC of the European Parliament and of the Council of 5 September 2007 (OJ 2007 L 247, p. 17).

(2)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67) in the version of Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 (OJ 2012 L 299, p. 1) applicable here.
Euro exchange rates (Source: reference exchange rate published by the ECB.) 11 August 2021 2021/C 324/04
Date: 2021-08-12
Institutions: European Commission
Subjects: euro, exchange rate, money








C_2021324EN.01000401.xml










12.8.2021   


EN


Official Journal of the European Union


C 324/4






Euro exchange rates (1)

11 August 2021
(2021/C 324/04)

1 euro =











 


Currency


Exchange rate




USD


US dollar


1,1718 




JPY


Japanese yen


129,68 




DKK


Danish krone


7,4373 




GBP


Pound sterling


0,84698 




SEK


Swedish krona


10,2305 




CHF


Swiss franc


1,0818 




ISK


Iceland króna


148,00 




NOK


Norwegian krone


10,4548 




BGN


Bulgarian lev


1,9558 




CZK


Czech koruna


25,405 




HUF


Hungarian forint


354,84 




PLN


Polish zloty


4,5858 




RON


Romanian leu


4,9163 




TRY


Turkish lira


10,1467 




AUD


Australian dollar


1,5958 




CAD


Canadian dollar


1,4677 




HKD


Hong Kong dollar


9,1187 




NZD


New Zealand dollar


1,6704 




SGD


Singapore dollar


1,5924 




KRW


South Korean won


1 357,41 




ZAR


South African rand


17,3326 




CNY


Chinese yuan renminbi


7,5996 




HRK


Croatian kuna


7,4955 




IDR


Indonesian rupiah


16 881,52 




MYR


Malaysian ringgit


4,9684 




PHP


Philippine peso


59,126 




RUB


Russian rouble


86,8412 




THB


Thai baht


39,062 




BRL


Brazilian real


6,1113 




MXN


Mexican peso


23,5291 




INR


Indian rupee


87,1605 






(1)  Source: reference exchange rate published by the ECB.
Dangerous substances - List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) in the second half of 2020 2021/C 324/09 Subcommittee I on the free movement of goods To be noted by the EEA Joint Committee
Date: 2021-08-12
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, chemical product, chemicals legislation, dangerous substance, health control, health risk, market approval, marketing standard








C_2021324EN.01001401.xml










12.8.2021   


EN


Official Journal of the European Union


C 324/14






Dangerous substances - List of authorisation decisions taken by the EEA EFTA States in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) in the second half of 2020
(2021/C 324/09)
Subcommittee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 25/2008 of 14 March 2008, the EEA Joint Committee is invited to note the following lists concerning authorisation decisions adopted on the basis of Article 64(8) of Regulation (EC) No 1907/2006 (REACH) for the period 1 July – 31 December 2020, at their meeting on 19 March 2021.




ANNEX
List of authorisation decisions
The following authorisation decisions in accordance with Article 64(8) of Regulation (EC) 1907/2006 (REACH) have been taken in the EEA EFTA States during the period 1 July – 31 December 2020:








Substance name


Commission decision under Article 64(8) of Regulation (EC) No 1907/2006


Country


Date of decision




Chromium trioxide


C(2020) 7104


Iceland


20.11.2020




Chromium trioxide


C(2020) 7104


Norway


10.11.2020




Sodium dichromate


C(2020) 5826


Iceland


21.9.2020




Sodium dichromate


C(2020) 5826


Liechtenstein


22.9.2020




Sodium dichromate


C(2020) 5826


Norway


25.9.2020




Sodium dichromate


C(2020) 6518


Iceland


14.10.2020




Sodium dichromate


C(2020) 6518


Liechtenstein


14.10.2020




Sodium dichromate


C(2020) 6518


Norway


29.10.2020




Strontium chromate


C(2020) 6231


Iceland


30.9.2020




Strontium chromate


C(2020) 6231


Liechtenstein


6.10.2020




Strontium chromate


C(2020) 6231


Norway


25.9.2020
Non-opposition to a notified concentration (Case M.10274 — EDFR/Lumani/GLD) (Text with EEA relevance) 2021/C 332/02
Date: 2021-08-12
Institutions: Directorate-General for Competition, European Commission
Subjects: France, economic concentration, energy production, investment company, merger control, photovoltaic cell, power plant, renewable energy, solar architecture, subsidiary








C_2021332EN.01000201.xml










18.8.2021   


EN


Official Journal of the European Union


C 332/2






Non-opposition to a notified concentration
(Case M.10274 — EDFR/Lumani/GLD)
(Text with EEA relevance)
(2021/C 332/02)
On 12 August 2021, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:






—


in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,










—


in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32021M10274. EUR-Lex is the online access to European law.






(1)  OJ L 24, 29.1.2004, p. 1.
Case C-495/21: Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12 August 2021 — L. GmbH v Federal Republic of Germany
Date: 2021-08-12
Institutions: Court of Justice
Subjects: health legislation, medical device, pharmaceutical legislation, pharmaceutical product








C_2021471EN.01002501.xml










22.11.2021   


EN


Official Journal of the European Union


C 471/25






Request for a preliminary ruling from the Bundesverwaltungsgericht (Germany) lodged on 12 August 2021 — L. GmbH v Federal Republic of Germany
(Case C-495/21)
(2021/C 471/31)
Language of the case: German

Referring court

Bundesverwaltungsgericht

Parties to the main proceedings


Appellant on a point of law: L. GmbH

Respondent in the appeal on a point of law: Federal Republic of Germany

Questions referred







1.


Can the principal intended action of a substance be pharmacological within the meaning of Article 1(2)(a) of Directive 93/42/EEC (1) even if it is not based on a receptor-mediated mode of action and the substance is not absorbed by the human body but remains on and reacts with the surface of, for example, the mucosa? On what criteria should a distinction be drawn between pharmacological and non-pharmacological means, in particular physico-chemical means, in such a case?










2.


Can a product be regarded as a substance-based medical device within the meaning of Article 1(2)(a) of Directive 93/42/EEC if, according to current scientific knowledge, the mode of action of the product is open to debate and it is thus not possible to definitively determine whether the principal intended action is achieved by pharmacological or physico-chemical means?










3.


In such a case, is the classification of the product as a medicinal product or as a medical device to be carried out on the basis of an overall assessment of its other properties and all other circumstances, or, in so far as it is intended to prevent, treat or alleviate diseases, is the product to be regarded as a medicinal product by presentation within the meaning of Article 1(2)(a) of Directive 2001/83/EC, (2) irrespective of whether or not a specific medicinal effect is being claimed?










4.


Does the primacy of the regime governing medicinal products also apply in such a case in accordance with Article 2(2) of Directive 2001/83/EC?






(1)  Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ 1993 L 169, p. 1), as last amended by Directive 2007/45/EC of the European Parliament and of the Council of 5 September 2007 (OJ 2007 L 247, p. 17).

(2)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67) in the version of Directive 2012/26/EU of the European Parliament and of the Council of 25 October 2012 (OJ 2012 L 299, p. 1) which is applicable here.
Case C-498/21 P: Appeal brought on 12 August 2021 by Birkenstock IP GmbH and Birkenstock Sales GmbH against the order of the General Court (Sixth Chamber) made on 2 June 2021 in Case T-365/20, Birkenstock Sales GmbH v European Union Intellectual Property Office
Date: 2021-08-12
Institutions: Court of Justice
Subjects: EU trade mark, clothing, footwear industry, leather, medical device, registered trade mark, trade-mark law








C_2022024EN.01001202.xml










17.1.2022   


EN


Official Journal of the European Union


C 24/12






Appeal brought on 12 August 2021 by Birkenstock IP GmbH and Birkenstock Sales GmbH against the order of the General Court (Sixth Chamber) made on 2 June 2021 in Case T-365/20, Birkenstock Sales GmbH v European Union Intellectual Property Office
(Case C-498/21 P)
(2022/C 24/17)
Language of the case: German

Parties


Appellants: Birkenstock IP GmbH, Birkenstock Sales GmbH (represented by: N. Weber and D. Leisner, Rechtsanwälte)

Other party to the proceedings: European Union Intellectual Property Office
By order of 22 November 2021, the Court of Justice of the European Union (Chamber determining whether appeals may proceed) did not allow the appeal to proceed and ordered the appellants to bear their own costs.
Commission Implementing Regulation (EU) 2021/1373 of 12 August 2021 entering a name in the register of protected designations of origin and protected geographical indications ‘Jászsági nyári szarvasgomba’ (PGI)
Date: 2021-08-12
Institutions: Directorate-General for Agriculture and Rural Development, European Commission
Subjects: Hungary, Northern Alföld, consumer information, designation of origin, labelling, mushroom-growing








L_2021296EN.01000101.xml










19.8.2021   


EN


Official Journal of the European Union


L 296/1








            COMMISSION IMPLEMENTING REGULATION (EU) 2021/1373
of 12 August 2021
         
entering a name in the register of protected designations of origin and protected geographical indications

            ‘Jászsági nyári szarvasgomba’ (PGI)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:







(1)


Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Hungary’s application to register the name ‘Jászsági nyári szarvasgomba’ was published in the Official Journal of the European Union (2).












(2)


As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Jászsági nyári szarvasgomba’ should therefore be entered in the register,





HAS ADOPTED THIS REGULATION:



Article 1
The name ‘Jászsági nyári szarvasgomba’ (PGI) is hereby entered in the register.
The name specified in the first paragraph denotes a product in Class 1.6. – Fruit, vegetables and cereals, fresh or processed, as listed in Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).


Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 12 August 2021.


For the Commission


On behalf of the President

Janusz WOJCIECHOWSKI
            

Member of the Commission






(1)  
            OJ L 343, 14.12.2012, p. 1.

(2)  
            OJ C 149, 27.4.2021, p. 11.

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).